SciSparc Ltd (SPRC) ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

According to the LOI, SciSparc’s pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV...

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV...